Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

Valeant Pharma (VRX) Outperforms Amid Broad Weakness

May 11, 2017 9:54 AM EDT

Valeant Pharma (NYSE: VRX) Outperforms Amid Broad Weakness

... More

Stifel Comments On Valeant (VRX) Earnings

May 9, 2017 10:25 AM EDT

Stifel maintains Buy on Valeant Pharmaceuticals (NYSE: VRX) price target of $45.00.

Analyst Annabel Samimy stands out as one of two sell-side analysts who is bullish on the name with a Buy rating. Samimy expects headwinds to persist through the end of 2017 from managed... More